|Bid||43.50 x 900|
|Ask||44.15 x 2200|
|Day's Range||43.67 - 44.94|
|52 Week Range||33.20 - 46.47|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||11.09|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||1.36 (3.02%)|
|1y Target Est||44.15|
Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
The company gave a nonprofit foundation money to cover Medicare copays for its pulmonary arterial hypertension drugs as it hiked the prices of those drugs and steered Medicare patients away from the company's own free drug program to the foundation.
Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.
Health-care stocks have found new life as markets crater. UnitedHealth UNH and Eli Lilly LLY roared to record highs on Tuesday, while Pfizer PFE and Merck MRK moved to their highest levels since 2001, although they were all down at least 1 percent in Thursday's premarket. Mark Newton , technical analyst at Newton Advisors, said Tuesday the overall health-care trade still looks like a solid play.
CSPC Pharmaceutical Group Ltd., which is bidding to provide drugs to Chinese cities in the program, tumbled 14 percent at the close in Hong Kong Thursday, its biggest decline since 2008. The MSCI China Health Care Index fell 8.4 percent, the biggest decline since 2009.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
AI is the buzzword these days, and the market has huge growth potential. PR Newswire, citing QY Research, reported that the global AI market could grow 52.6% (compounded annually) from $2.65 billion in 2017 to $78 billion by 2025. IBM (IBM) has been the largest player in the AI market.
U.S. stock futures and options trading volume are galloping higher following a promising turn in the trade war. During their meeting at the G-20 summit over the weekend, President Donald Trump and Chinese president Xi Jinping agreed to halt additional tariffs after Jan. 1.
By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...
NEW YORK-- -- 26-week data from the ongoing 52-week REFLECTIONS B328-06 study met its primary endpoint, demonstrating comparable safety and efficacy for patients with indolent follicular lymphoma The U.S. Food and Drug Administration accepted for review, a Biologics License Application for PF-05280586 in September 2018 Pfizer Inc. announced today at the American Society of Hematology Annual Meeting ...
Pfizer won't be able to access the U.S. market with its biosimilar version until late 2023, providing AbbVie with additional years of exclusivity and strong cash flows.
The stock market shrugged off early weakness Friday to finish with solid gains. It sought direction as traders look ahead to this weekend's G20 summit.
Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.
One of the healthcare stocks that's been leading the pack higher this year is pharmaceutical giant Pfizer Inc. Pfizer has been a much needed pocket of low-volatility outperformance for investors in recent months, a stretch when investors' risk tolerance has been tightening. The good news is that Pfizer's leadership status in this market environment isn't showing any signs of fatiguing - in fact, shares just pushed into breakout territory this week.
Array BioPharma (ARRY) incurred a cost of goods sold of $195,000 in the first quarter of fiscal 2019. For fiscals 2019 and 2020, the company’s gross margins are expected to be 96.93% and 95.97%, respectively. In comparison, the fiscal 2019 gross margins of its peers Amgen (AMGN), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to be 85.68%, 70.65%, and 79.31%, respectively.
In November, of the total eight analysts covering Array BioPharma (ARRY), four analysts have given Array stock “strong buy” ratings, and four have given it “buy” ratings.